trending Market Intelligence /marketintelligence/en/news-insights/trending/icpb_iK5xn5SU5XH6QmXqQ2 content esgSubNav
In This List

Mallinckrodt settles DOJ probe into sales, marketing activities for Acthar gel

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Mallinckrodt settles DOJ probe into sales, marketing activities for Acthar gel

Mallinckrodt PLC said it finalized a deal with the U.S. Justice Department to settle an investigation into Questcor Pharmaceuticals Inc.'s marketing of its Acthar gel.

The U.K.-based pharmaceutical company acquired Acthar — primarily used to treat infant spasms, multiple sclerosis and certain other conditions — when it bought Questcor in August 2014.

In March, the DOJ joined two whistleblower lawsuits alleging that Questcor bribed doctors to prescribe the blockbuster drug and defrauded the U.S. Medicare program by illegally marketing the product.

Mallinckrodt agreed to pay $15.4 million under the settlement to resolve the department's investigation. The deal does not include any admission of wrongdoing.

The drugmaker also previously said the settlement does not cover a recent civil claim filed by the DOJ related to alleged improper conduct at a Questcor charitable foundation between 2010 and 2014.

Mallinckrodt is also one of the opioid makers ordered to face an October trial to determine whether the companies' marketing practices contributed to the U.S. opioid crisis.